Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion

por Lloyd Clark, W., Liu, Mimi, Kitchens, John, Wang, Pin-wen, Haskova, Zdenka
Publicado en BMC Ophthalmol (2019)

Deep learning algorithm predicts diabetic retinopathy progression in individual patients

por Arcadu, Filippo, Benmansour, Fethallah, Maunz, Andreas, Willis, Jeff, Haskova, Zdenka, Prunotto, Marco
Publicado en NPJ Digit Med (2019)

Author Correction: Deep learning algorithm predicts diabetic retinopathy progression in individual patients

por Arcadu, Filippo, Benmansour, Fethallah, Maunz, Andreas, Willis, Jeff, Haskova, Zdenka, Prunotto, Marco
Publicado en NPJ Digit Med (2020)

SD-OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema due to Retinal Vein Occlusion

por Yiu, Glenn, Welch, R. Joel, Wang, Yinwen, Wang, Zhe, Wang, Pin-Wen, Haskova, Zdenka
Publicado en Ophthalmol Retina (2019)

LOCAL TREATMENT WITH ALPHA-MELANOCYTE STIMULATING HORMONE REDUCES CORNEAL ALLOREJECTION

por Hamrah, Pedram, Haskova, Zdenka, Taylor, Andrew W., Zhang, Qiang, Ksander, Bruce R., Dana, M. Reza
Publicado 2009

Vision-Related Functional Burden of Diabetic Retinopathy Across Severity Levels in the United States

por Willis, Jeffrey R., Doan, Quan V., Gleeson, Michelle, Haskova, Zdenka, Ramulu, Pradeep, Morse, Lawrence, Cantrell, Ronald A.
Publicado en JAMA Ophthalmol (2017)

CALCINEURIN INHIBITORS AUGMENT ENDOTHELIAL-TO-MESENCHYMAL TRANSITION BY ENHANCING PROLIFERATION IN ASSOCIATION WITH CYTOKINE-MEDIATED ACTIVATION

por Woda, Craig B, Bruneau, Sarah, Mak, Anne Linde, Haskova, Zdenka, Liu, Kaifeng, Ghosh, Chandra C., Briscoe, David M
Publicado en Biochem Biophys Res Commun (2019)

Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials

por Singer, Michael, Liu, Mimi, Schlottmann, Patricio G, Khanani, Arshad M, Hemphill, Miranda, Hill, Lauren, Tuomi, Lisa, Haskova, Zdenka
Publicado en Clin Ophthalmol (2020)

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial

por Khanani, Arshad M., Patel, Sunil S., Ferrone, Philip J., Osborne, Aaron, Sahni, Jayashree, Grzeschik, Susanna, Basu, Karen, Ehrlich, Jason S., Haskova, Zdenka, Dugel, Pravin U.
Publicado en JAMA Ophthalmol (2020)

Vascular Safety of Ranibizumab in Patients With Diabetic Macular Edema: A Pooled Analysis of Patient-Level Data From Randomized Clinical Trials

por Zarbin, Marco A., Dunger-Baldauf, Cornelia, Haskova, Zdenka, Koovejee, Prashil, Mousseau, Marie-Catherine, Margaron, Philippe, Snow, Howard, Beaumont, Paul E., Staurenghi, Giovanni, Francom, Steven
Publicado en JAMA Ophthalmol (2017)

Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin

por Srivastava, Shivani, Pelloso, David, Feng, Hailin, Voiles, Larry, Lewis, David, Haskova, Zdenka, Whitacre, Margaret, Trulli, Stephen, Chen, Yi-Jiun, Toso, John, Jonak, Zdenka L., Chang, Hua-Chen, Robertson, Michael J.
Publicado 2013